Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 5, 2007, Pages 999-1003

  Silley, Peter ^a,b   Stephan, Bernd ^c   Greife, Heinrich A ^c   Pridmore, Andrew ^d  

^a MB Consult Limited   (United Kingdom)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c BAYER PHARMA AG   (Germany)

^d Don Whitley Scientific Limited   (United Kingdom)

Author keywords

Anaerobes; Companion animals; Fluoroquinolones

Indexed keywords

DIFLOXACIN; ENROFLOXACIN; IBAFLOXACIN; MARBOFLOXACIN; MOXIFLOXACIN; PRADOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CAT; CONTROLLED STUDY; DOG; DRUG STRUCTURE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRUCTURE ANALYSIS; VETERINARY MEDICINE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; CAT DISEASES; CATS; DOG DISEASES; DOGS; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE;

EID: 35448962597     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm346     Document Type: Article

References (25)

1. Lesher GY, Froelich EJ, Gruett MD et al. 1, 8-Naphthyridine derivatives: A new class of chemotherapeutic agents. J Med Pharm Chem 1962; 5: 1063-5.
2. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'. J Antimicrob Chemother 1999; 43 Suppl B: 1-11.
3. Cambau E, Bordon F, Collatz E et al. Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid. Antimicrob Agents Chemother 1993; 37: 1247-52.
4. Gautier-Bouchardon AV, Reinhardt AK,, Kobisch M et al. In vitro development of resistance to enrofloxacin, erythromycin, tylosin, tiamulin and oxytetracycline in Mycoplasma gallisepticum, Mycoplasma iowae and Mycoplasma synoviae. Vet Microbiol 2002; 88: 47-58.
5. Hannan PCT, Windsor GD, Jong de A et al. Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones. Antimictob Agents Chemother 1997; 41: 2037-40.
6. Rolain J-M, Stuhl L, Maurin M et al. Evaluation of antibiotic susceptibilities of three rickettsial species including Rickettsia felis by a quantitative PCR DNA assay. Antimicrob Agents Chemother 2002; 46: 2747-51.
7. Hawkey PM. Mechanisms of quinolone action and microbial response. J Antimicrob Chermother 2003; 51 Suppl S1: 29-35.
8. Drlica K, Malik M. Fluoroquinolones: Action and resistance. Curr Top Med Chem 2003; 3: 249-82.
9. Lu T, Zhao X, Li X et al. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: Action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45: 2703-9.
10. Greene CE, Budsberg SC. Veterinary use of quinolones. In: Hooper DC, Wolfson JS, eds. Quinolone Antimicrobial Agents. 2nd edn. Washington, DC: American Society for Microbiology Press, 1993; 473-88.
11. Stephan B, Friederichs S, Pridmore A et al. Novel fluoroquinolone pradofloxacin: Clinical efficacy and safety in the treatment of feline wound infections. J Vet Pharmacol Therap 2006; 29 Suppl 1: 77-8.
12. Wetzstein H-G. Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance. Antimicrob Agents Chemother 2005; 49: 4166-73.
13. Stephan B, Greife HA, Pridmore A et al. Mutant prevention concentration of pradofloxacin against Porphyromonas gingivalis. Vet Microbiol 2007; 121: 194-5.
14. National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria - Fifth Edition: Approved Standard M11-A5. NCCLS, Wayne, PA, USA, 2001.
15. Appelbaum PC. Quinolone activity against anaerobes. Drugs 1999; 58 Suppl 2: 60-4.
16. Ednie LM, Jacobs MR, Appelbaum PC. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother 1998; 42: 2459-62.
17. Goldstein EJC, Citron DM, Warren YA et al. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006; 50: 148-52.
18. Goldstein EJC. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infectons: Review of current information on efficacy and safety. Clin Infect Dis 1996; 23: S25-30.
19. Wexler HM, Molitoris E, Molitoris D et al. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob Agents Chemother 1996; 40: 2232-5.
20. Goldstein EJC, Citron DM, Hudspeth M et al. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic, human and animal bite-wound pathogens. J Antimicrob Chemother 1998; 41: 391-6.
21. Aldridge KE, Ashcraft DS. Comparison of the in vitro activities of BAY 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997; 41: 709-11.
22. Ackermann G, Schaumann R, Pless B et al. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis 2000; 19: 228-32.
23. Milazzo I, Blandino G, Musumeci R et al. Antibacterial activity of moxifloxacin against periodontal anaerobic pathogens involved in systersic infections. Int J Antimicrob Agents 2002; 20: 451-6.
24. Goldstein EJC. Review of the in vitro activity of gemifloxacin against Gram-positive and Gram-negative anaerobic pathogens. J Antimicrob Chemother 2000 45 Suppl 1:55-65.
25. King A, Downes J, Nord C-E et al. Antimicrobial susceptibility of non-Bacteroides fragilis group anaerobic Gram-negative bacilli in Europe. Clin Microbiol Infect 1999; 5: 404-16.